Immunomodulation with IL-2 and Interferon-alpha in Cancer Patients
Author Information
Author(s): A. von Rohr, A.K. Ghosh, N. Thatcher, P.L. Stern
Primary Institution: Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute, Manchester, UK
Hypothesis
Can combined treatment with interleukin-2 and interferon-alpha enhance immune response in patients with advanced malignancies?
Conclusion
The treatment resulted in significant immunomodulation and higher cytotoxicity levels in patients who responded to therapy.
Supporting Evidence
- Patients showed increased cytotoxicity against K562 and Daudi target cells after treatment.
- Responders had higher levels of CD 56+ lymphocytes compared to non-responders.
- Statistically significant increases in immune parameters were observed during treatment.
Takeaway
Doctors gave patients two medicines to help their immune system fight cancer, and it worked better for some patients than others.
Methodology
Patients received subcutaneous IL-2 and interferon-alpha, with blood samples taken for immune parameter analysis.
Limitations
The study involved a small number of patients and focused only on immunological aspects without detailed clinical data.
Participant Demographics
Patients had advanced malignant melanoma or renal cell cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website